BRISTOL MYERS SQUIBB CO XBRL Taxonomy Presentation Networks

-Network: (11 - Statement - Statement Of Income Alternative)
-Income Statement [Abstract] {ID1}
-Statement [Table] {ID2}
-Statement [Line Items] {ID3}
-EARNINGS {ID4}
Net Sales {ID5}
Cost of products sold {ID6}
Marketing, selling and administrative {ID7}
Advertising and product promotion {ID8}
Research and development {ID9}
Acquired in-process research and development {ID10}
Provision for restructuring, net {ID11}
Litigation expense, net {ID12}
Equity in net income of affiliates {ID13}
Other (income)/expense, net {ID14}
Total Expenses, net {ID15}
Earnings from Continuing Operations Before Income Taxes {ID16}
Provision for income taxes {ID17}
Net Earnings from Continuing Operations {ID18}
-Discontinued Operations: {ID19}
Earnings, net of taxes {ID20}
Loss on Disposal, net of taxes {ID21}
Net Earnings from Discontinued Operations {ID22}
Net Earnings {ID23}
Net Earnings Attributable to Noncontrolling Interest {ID24}
Net Earnings Attributable to Bristol-Myers Squibb Company {ID25}
-Earnings per Common Share from Continuing Operations Attributable to Bristol-Myers Squibb Company: {ID26}
Basic {ID27}
Diluted {ID28}
-Earnings per Common Share Attributable to Bristol-Myers Squibb Company: {ID29}
Basic {ID30}
Diluted {ID31}
Dividends declared per common share {ID32}
-Network: (12 - Statement - Statement Of Other Comprehensive Income)
-Statement of Income and Comprehensive Income [Abstract] {ID33}
-Statement [Table] {ID34}
-Statement [Line Items] {ID35}
-COMPREHENSIVE INCOME {ID36}
Net earnings {ID37}
-Other Comprehensive Income/(Loss): {ID38}
Foreign currency translation {ID39}
Foreign currency translation on hedge of a net investment {ID40}
Derivatives qualifying as cash flow hedges, net of taxes of $15 and $16 for the three months ended June 30, 2009 and 2008, respectively; and $2 and $19 for the six months ended June 30, 2009 and 2008, respectively {ID41}
Derivatives qualifying as cash flow hedges reclassified to net earnings, net of taxes of $7 and $11 for the three months ended June 30, 2009 and 2008, respectively; and $14 and $16 for the six months ended June 30, 2009 and 2008, respectively {ID42}
Pension and postretirement benefits, net of taxes of $160 and $9 for the three months ended June 30, 2009 and 2008, respectively; and $220 and $9 for the six months ended June 30, 2009 and 2008, respectively {ID43}
Pension and postretirement benefits reclassified to net earnings, net of taxes of $20 and $11 for the three months ended June 30, 2009 and 2008, respectively; and $37 and $17 for the six months ended June 30, 2009 and 2008, respectively {ID44}
Available for sale securities, net of taxes of $4 and $3 for the three months ended June 30, 2009 and 2008, respectively; and $5 and $1 for the six months ended June 30, 2009 and 2008, respectively {ID45}
Total Other Comprehensive Income/(Loss) {ID46}
Comprehensive Income {ID47}
Comprehensive Income Attributable to Noncontrolling Interest {ID48}
Comprehensive Income Attributable to Bristol-Myers Squibb Company {ID49}
-RETAINED EARNINGS {ID50}
Retained Earnings at January 1 {ID51}
Net Earnings Attributable to Bristol-Myers Squibb Company {ID52}
Cash dividends declared {ID53}
Retained Earnings at June 30 {ID54}
-Network: (13 - Statement - Statement Of Other Comprehensive Income (Parenthetical))
-Statement of Income and Comprehensive Income [Abstract] {ID55}
-Statement [Table] {ID56}
-Statement [Line Items] {ID57}
Derivatives qualifying as cash flow hedges, taxes {ID58}
Derivatives qualifying as cash flow hedges reclassified to net earnings, taxes {ID59}
Pension and postretirement benefits, taxes {ID60}
Pension and postretirement benefits reclassified to net earnings, taxes {ID61}
Available for sale securities, taxes {ID62}
-Network: (14 - Statement - Statement Of Financial Position Classified)
-Statement of Financial Position [Abstract] {ID63}
-Statement [Table] {ID64}
-Statement [Line Items] {ID65}
-ASSETS {ID66}
-Current Assets: {ID67}
Cash and cash equivalents {ID68}
Marketable securities {ID69}
Receivables, net of allowances of $130 in 2009 and $128 in 2008 {ID70}
Inventories, net {ID71}
Deferred income taxes, net of valuation allowances {ID72}
Prepaid expenses {ID73}
Total Current Assets {ID74}
Property, plant and equipment, net {ID75}
Goodwill {ID76}
Other intangible assets, net of accumulated amortization of $1,912 in 2009 and $1,802 in 2008 {ID77}
Deferred income taxes, net of valuation allowances {ID78}
Marketable securities {ID79}
Other assets {ID80}
Total Assets {ID81}
-LIABILITIES {ID82}
-Current Liabilities: {ID83}
Short-term borrowings {ID84}
Accounts payable {ID85}
Accrued expenses {ID86}
Deferred income {ID87}
Accrued rebates and returns {ID88}
U.S. and foreign income taxes payable {ID89}
Dividends payable {ID90}
Accrued litigation liabilities {ID91}
Total Current Liabilities {ID92}
Pension, postretirement and postemployment liabilities {ID93}
Deferred income {ID94}
U.S. and foreign income taxes payable {ID95}
Other liabilities {ID96}
Long-term debt {ID97}
Total Liabilities {ID98}
Commitments and contingencies (Note 21) {ID99}
-EQUITY {ID100}
-Bristol-Myers Squibb Company Shareholders' Equity: {ID101}
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 5,664 in 2009 and 5,668 in 2008, liquidation value of $50 per share {ID102}
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2009 and 2008 {ID103}
Capital in excess of par value of stock {ID104}
Restricted stock {ID105}
Accumulated other comprehensive loss {ID106}
Retained earnings {ID107}
Less cost of treasury stock -224 million common shares in 2009 and 226 million in 2008 {ID108}
Total Bristol-Myers Squibb Company Shareholders' Equity {ID109}
Noncontrolling interest {ID110}
Total Equity {ID111}
Total Liabilities and Equity {ID112}
-Network: (15 - Statement - Statement Of Financial Position Classified (Parenthetical))
-Statement of Financial Position [Abstract] {ID113}
-Statement [Table] {ID114}
-Statement [Line Items] {ID115}
Receivables, allowances {ID116}
Other intangible assets, accumulated amortization {ID117}
Preferred stock, $2 convertible series, par value {ID118}
Preferred stock, $2 convertible series, Authorized {ID119}
Preferred stock, $2 convertible series, issued {ID120}
Preferred stock, $2 convertible series, outstanding {ID121}
Preferred stock, $2 convertible series, liquidation value {ID122}
Common stock, par value {ID123}
Common stock, Authorized {ID124}
Common stock, issued {ID125}
Treasury stock, common shares {ID126}
-Network: (16 - Statement - Statement Of Cash Flows Indirect)
-Statement of Cash Flows [Abstract] {ID127}
-Statement [Table] {ID128}
-Statement [Line Items] {ID129}
-Cash Flows From Operating Activities: {ID130}
Net earnings {ID131}
-Adjustments to reconcile net earnings to net cash provided by operating activities: {ID132}
Net earnings attributable to noncontrolling interest {ID133}
Depreciation {ID134}
Amortization {ID135}
Deferred income tax expense {ID136}
Stock-based compensation expense {ID137}
Impairment charges {ID138}
Gain on sale of product lines and businesses {ID139}
Gain on debt buyback and interest swap terminations {ID140}
Gain on sale of property, plant and equipment and investment in other companies {ID141}
Acquired in-process research and development {ID142}
-Changes in operating assets and liabilities: {ID143}
Receivables {ID144}
Inventories {ID145}
Deferred income {ID146}
Accounts payable {ID147}
U.S. and foreign income taxes payable {ID148}
Changes in other operating assets and liabilities {ID149}
Net Cash Provided by Operating Activities {ID150}
-Cash Flows From Investing Activities: {ID151}
Proceeds from sale of marketable securities {ID152}
Purchases of marketable securities {ID153}
Additions to property, plant and equipment and capitalized software {ID154}
Proceeds from sale of property, plant and equipment and investment in other companies {ID155}
Proceeds from sale of product lines and businesses {ID156}
Purchase of Kosan Biosciences, Inc., net {ID157}
Proceeds from sale and leaseback of properties {ID158}
Net Cash (Used in)/Provided by Investing Activities {ID159}
-Cash Flows From Financing Activities: {ID160}
Short-term debt repayments {ID161}
Long-term debt borrowings {ID162}
Long-term debt repayments {ID163}
Interest rate swap termination {ID164}
Issuances of common stock under stock plans and excess tax benefits from share-based payment arrangements {ID165}
Dividends paid {ID166}
Proceeds from Mead Johnson initial public offering {ID167}
Net Cash (Used in)/Provided by Financing Activities {ID168}
Effect of Exchange Rates on Cash and Cash Equivalents {ID169}
(Decrease)/Increase in Cash and Cash Equivalents {ID170}
Cash and Cash Equivalents at Beginning of Period {ID171}
Cash and Cash Equivalents at End of Period {ID172}
-Network: (17 - Disclosure - Notes to Financial Statements)
-Notes to Financial Statements [Abstract] {ID173}
Note 1. Basis of Presentation and New Accounting Standards {ID174}
Note 2. Alliances and Collaborations {ID175}
Note 3. Business Segments {ID176}
Note 4. Restructuring {ID177}
Note 5. Mead Johnson Nutrition Company Initial Public Offering {ID178}
Note 6. Discontinued Operations {ID179}
Note 7. Earnings Per Share {ID180}
Note 8. Other (Income)/Expense, Net {ID181}
Note 9. Income Taxes {ID182}
Note 10. Fair Value Measurement {ID183}
Note 11. Cash, Cash Equivalents and Marketable Securities {ID184}
Note 12. Receivables, Net {ID185}
Note 13. Inventories, Net {ID186}
Note 14. Property, Plant and Equipment, Net {ID187}
Note 15. Accrued Expenses {ID188}
Note 16. Equity {ID189}
Note 17. Pension, Postretirement and Postemployment Liabilities {ID190}
Note 18. Employee Stock Benefit Plans {ID191}
Note 19. Short-Term Borrowings and Long-Term Debt {ID192}
Note 20. Financial Instruments {ID193}
Note 21. Legal Proceedings and Contingencies {ID194}
Note 22. Subsequent Event {ID195}
-Network: (18 - Document - Document Information)
-Document Information [Text Block] {ID196}
Document Type {ID197}
Amendment Flag {ID198}
Amendment Description {ID199}
Document Period End Date {ID200}
-Network: (19 - Document - Entity Information)
-Entity [Text Block] {ID201}
Trading Symbol {ID202}
Entity Registrant Name {ID203}
Entity Central Index Key {ID204}
Current Fiscal Year End Date {ID205}
Entity Well-known Seasoned Issuer {ID206}
Entity Current Reporting Status {ID207}
Entity Voluntary Filers {ID208}
Entity Filer Category {ID209}
Entity Common Stock, Shares Outstanding {ID210}
Entity Public Float {ID211}